A liquid crystal of ascorbyl palmitate used as vaccine platform, provides controlled release of antigen

MARÍA V. AGUIRRE; MARÍA F. SÁNCHEZ VALLECILLO; ANA L. CHIODETTI; MARÍA M. MINGUITO DE LA ESCALERA; CARLOS ARDAVÍN; SANTIAGO D. PALMA; GABRIEL MORÓN; DANIEL A. ALLEMANDI2; MARÍA C. PISTORESI-PALENCIA; BELKYS A. MALETTO

Buenos Aires

Congreso; Latin American Society for Immunodeficiencies (LASID), Sociedad Argentina de Inmunologia (SAI), French Society for Immunology (SFI); 2015

Sociedad Argentina de Inmunologia

Modern subunit vaccines require the development of new adjuvant strategies. CpG-ODN formulated with a liquid crystal nanostructure, formed by self-assembly of 6-O-ascorbyl palmitate (Coa-ASC16), is an attractive adjuvant system. We previously showed that Coa-ASC16 improves CpG-ODN´s adjuvant activity; however, we still do not exactly understand how Coa-ASC16 operates. CoaASC16 alone is sensed by the innate immunity, triggering an inflammatory response at the injection site depending on MyD88 protein. The purpose of the present study was to uncover the mechanisms underlying the enhanced immune response by the formulation with Coa-ASC16. We determined antigen persistence at the injection site by in vivo near-infrared fluorescent imaging. Mice were subcutaneously injected with soluble dye-OVA or dye-OVA formulated with CoaASC16. The fluorescent signal of dye-OVA remaining at the injection site (expressed as % of maximum recorded value) was 4.8±0.8 vs 100±0 (p